ABIO vs. BMRA, NYMX, OCX, TRIB, ICCC, NAVB, VRAX, LHDX, AWH, and MYMD
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Biomerica (BMRA), Nymox Pharmaceutical (NYMX), OncoCyte (OCX), Trinity Biotech (TRIB), ImmuCell (ICCC), Navidea Biopharmaceuticals (NAVB), Virax Biolabs Group (VRAX), Lucira Health (LHDX), Aspira Women's Health (AWH), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry.
ARCA biopharma vs.
Biomerica (NASDAQ:BMRA) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
Biomerica has higher revenue and earnings than ARCA biopharma. Biomerica is trading at a lower price-to-earnings ratio than ARCA biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, ARCA biopharma had 3 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for ARCA biopharma and 1 mentions for Biomerica. Biomerica's average media sentiment score of 1.11 beat ARCA biopharma's score of 0.58 indicating that Biomerica is being referred to more favorably in the media.
Biomerica has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
ARCA biopharma has a net margin of 0.00% compared to Biomerica's net margin of -34.58%. ARCA biopharma's return on equity of -22.39% beat Biomerica's return on equity.
Biomerica received 14 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 51.46% of users gave ARCA biopharma an outperform vote.
22.0% of Biomerica shares are held by institutional investors. Comparatively, 15.4% of ARCA biopharma shares are held by institutional investors. 15.7% of Biomerica shares are held by insiders. Comparatively, 20.3% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Biomerica and ARCA biopharma tied by winning 7 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ARCA biopharma Competitors List